JP2021523170A5 - - Google Patents

Info

Publication number
JP2021523170A5
JP2021523170A5 JP2020563542A JP2020563542A JP2021523170A5 JP 2021523170 A5 JP2021523170 A5 JP 2021523170A5 JP 2020563542 A JP2020563542 A JP 2020563542A JP 2020563542 A JP2020563542 A JP 2020563542A JP 2021523170 A5 JP2021523170 A5 JP 2021523170A5
Authority
JP
Japan
Prior art keywords
individual
neutralizing agent
combination according
nkg2a
tumor
Prior art date
Application number
JP2020563542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523170A (ja
JPWO2019219658A5 (https=
JP7531404B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/062305 external-priority patent/WO2019219658A1/en
Publication of JP2021523170A publication Critical patent/JP2021523170A/ja
Publication of JP2021523170A5 publication Critical patent/JP2021523170A5/ja
Publication of JPWO2019219658A5 publication Critical patent/JPWO2019219658A5/ja
Priority to JP2024059910A priority Critical patent/JP2024102055A/ja
Application granted granted Critical
Publication of JP7531404B2 publication Critical patent/JP7531404B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020563542A 2018-05-15 2019-05-14 癌の処置 Active JP7531404B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024059910A JP2024102055A (ja) 2018-05-15 2024-04-03 癌の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671521P 2018-05-15 2018-05-15
US62/671,521 2018-05-15
PCT/EP2019/062305 WO2019219658A1 (en) 2018-05-15 2019-05-14 Treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024059910A Division JP2024102055A (ja) 2018-05-15 2024-04-03 癌の処置

Publications (4)

Publication Number Publication Date
JP2021523170A JP2021523170A (ja) 2021-09-02
JP2021523170A5 true JP2021523170A5 (https=) 2022-05-26
JPWO2019219658A5 JPWO2019219658A5 (https=) 2022-05-26
JP7531404B2 JP7531404B2 (ja) 2024-08-09

Family

ID=66752041

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020563542A Active JP7531404B2 (ja) 2018-05-15 2019-05-14 癌の処置
JP2024059910A Pending JP2024102055A (ja) 2018-05-15 2024-04-03 癌の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024059910A Pending JP2024102055A (ja) 2018-05-15 2024-04-03 癌の処置

Country Status (13)

Country Link
US (1) US12209126B2 (https=)
EP (1) EP3793607A1 (https=)
JP (2) JP7531404B2 (https=)
KR (1) KR102885515B1 (https=)
CN (1) CN112203691A (https=)
AU (2) AU2019270277B9 (https=)
CA (1) CA3099820A1 (https=)
EA (1) EA202092696A1 (https=)
IL (1) IL278618B2 (https=)
MA (1) MA52627A (https=)
SG (1) SG11202011117VA (https=)
TW (1) TW202011989A (https=)
WO (1) WO2019219658A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2959463A1 (en) 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
EA202092147A1 (ru) 2018-03-13 2021-03-04 Иннейт Фарма Лечение рака головы и шеи
CN113583127A (zh) * 2020-04-30 2021-11-02 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
WO2021228177A1 (en) * 2020-05-13 2021-11-18 Nanjing Legend Biotech Co., Ltd. Compositions and methods for reducing host rejection of allogeneic cells using simian icp47 and variants thereof
CN117730094A (zh) * 2021-07-16 2024-03-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
US20250270317A1 (en) * 2021-10-04 2025-08-28 Les Laboratoires Servier Cancer therapy targeting nkg2a
JP2025500845A (ja) * 2021-12-14 2025-01-15 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション Ｃｄ９４／ｎｋｇ２ａヘテロ二量体ポリペプチドに結合する分子

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
AU2005321017B2 (en) 2004-12-28 2011-02-24 Innate Pharma S.A. Monoclonal antibodies against NKG2A
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CN101484471B (zh) 2006-06-30 2013-11-06 诺沃-诺迪斯克有限公司 抗-nkg2a抗体及其用途
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
EP2628753A1 (en) 2008-01-24 2013-08-21 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
KR102047248B1 (ko) 2011-06-17 2019-11-21 노보 노르디스크 에이/에스 침식성 세포의 선택적 제거
JP2017533255A (ja) 2014-08-28 2017-11-09 アカデミス・ジーケンハイス・ライデン・ハー・オー・デー・エヌ・エルユーエムセーＡｃａｄｅｍｉｓｃｈ Ｚｉｅｋｅｎｈｕｉｓ Ｌｅｉｄｅｎ Ｈ．Ｏ．Ｄ．Ｎ． Ｌｕｍｃ Ｃｄ９４／ｎｋｇ２ａおよび／またはｃｄ９４／ｎｋｇ２ｂ抗体、ワクチンの組み合わせ
CA2959463A1 (en) 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
SMT202000562T1 (it) 2014-09-16 2020-11-10 Innate Pharma Neutralizzazionne delle vie inibitorie nei linfociti
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
CA3012055A1 (en) 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
EA202092147A1 (ru) 2018-03-13 2021-03-04 Иннейт Фарма Лечение рака головы и шеи

Similar Documents

Publication Publication Date Title
JP2021523170A5 (https=)
JP2024102055A5 (https=)
IL278618B1 (en) Cancer treatment
JP2018518454A5 (https=)
CN114173815A (zh) 可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的联合疗法中的用途
JP2018501197A5 (https=)
JP2020514310A5 (https=)
JP2022513420A5 (https=)
JP2020502271A5 (https=)
US20250032633A1 (en) Antibody-drug conjugate and application thereof
TW201545758A (zh) 腫瘤免疫力之調節
HRP20160082T1 (hr) Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
EP3504244A1 (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
JP2018515137A5 (https=)
JPWO2020014460A5 (https=)
TW201925230A (zh) 以抗egfr療法治療癌症的組成物及方法
AU2021378793B2 (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
CN109663130B (zh) Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
EP3145544B1 (en) Ang2 antibodies
JPWO2020216697A5 (https=)
JPWO2019219658A5 (https=)
CN115485298A (zh) 用于治疗癌症的egfr抑制剂和ror1抑制剂的组合
US20210023211A1 (en) Combination of anti-fgfr4-antibody and bile acid sequestrant
JPWO2021089588A5 (https=)
TW202432585A (zh) 癌症新輔助治療的組合物及方法